Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 Phase II/III Randomized Controlled Trials

Martedì 26 maggio 2020 ca. 1 min. di lettura

Journal and Affiliations:

Cancer Treatment Reviews, 26 maggio 2020

Maria Luisa Gasparri, Università della Svizzera Italiana, Lugano’

Tags: [none]
Authors:
Maria Luisa Gasparri
Link: Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 Phase II/III Randomized Controlled Trials